ADVANCED ESOPHAGEAL ADENOCARCINOMA
Clinical trials for ADVANCED ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in stomach cancer trial
Disease control Recruiting nowThis study tests whether adding the drug ivonescimab to standard chemotherapy can shrink tumors better than chemo alone in people with advanced stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is to see how many patie…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New pill targets common cancer driver in advanced tumors
Disease control Recruiting nowThis early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: ADVANCED ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC